Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04576793 · ClinicalTrials.gov registry record · Phase 2
Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease
A Phase 2 study of Alzheimer Disease, sponsored by Patrick Lao.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT04576793 is a Phase 2 study of Alzheimer Disease that is actively recruiting participants, run by Patrick Lao. The registered enrollment target is 100 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04576793, a Phase 2 study of Alzheimer Disease, is actively recruiting participants, sponsored by Patrick Lao.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine how inflammation is related to other changes in the brain that occur during the progression of Alzheimer's disease. The investigators are also studying how inflammation is related to the symptoms that first occur in patients with Alzheimer's disease (AD). For this reason, the investigators are asking people with different versions of Alzheimer's disease and/or other related dementias to participate. This includes patients with: * Mild Cognitive Impairment * Posterior cortical atrophy - a version of Alzheimer's disease with vision difficulties * Logopenic variant primary progressive aphasia - a version of Alzheimer's disease with language difficulties * Amnestic Alzheimer's disease - a "typical" version of Alzheimer's disease with memory difficulties * The investigators are also enrolling older adults with normal visual, language, and memory function.
Conditions Studied
Interventions
- PROCEDURE Lumbar Puncture
- DRUG 11C-ER176
- DRUG 18F-MK6240
- DRUG 18F-Florbetaben
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2020-11-17 |
| Est. Completion | 2026-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04576793
The ClinicalTrials.gov registry entry for NCT04576793 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (96% lower). The listed sponsor is Patrick Lao, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 4 interventions - of which Lumbar Puncture is the first listed.
NCT04576793 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04576793 about?
NCT04576793 is a clinical study titled "Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease". The purpose of this study is to determine how inflammation is related to other changes in the brain that occur during the progression of Alzheimer's disease. The investigators are also studying how inflammation is related to the symptoms that first occur in patients with Alzheimer's disease (AD). Fo...
What is the current status of trial NCT04576793?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2020-11-17. Estimated completion is 2026-05-31.
What conditions does trial NCT04576793 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT04576793?
The interventions under investigation include: Lumbar Puncture (PROCEDURE), 11C-ER176 (DRUG), 18F-MK6240 (DRUG), 18F-Florbetaben (DRUG).
Who is sponsoring clinical trial NCT04576793?
This trial is sponsored by Patrick Lao, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04576793 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
RECRUITING · Phase 2
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
RECRUITING · Phase 2
-
Sleep Trial to Prevent Alzheimer's Disease
RECRUITING · Phase 2
-
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
RECRUITING · Phase 2
-
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.